THE EFFECT OF SULINDAC ON DERMAL RESPONSES TO BRADYKININ IN NORMAL SUBJECTS GIVEN AN ANGIOTENSIN CONVERTING-ENZYME-INHIBITOR

The ability of sulindac to modify the weal response to four doses of intradermal bradykinin in subjects given enalapril was tested in a double‐blind cross‐over study in normal volunteers. The dose‐dependent increase in skin thickness after bradykinin was significantly reduced by prior administration of sulindac. Certain of the actions and adverse effects of angiotensin converting enzyme inhibitors may be due to the interaction of prostaglandins and bradykinin. 1990 The British Pharmacological Society